Valuation: Mineralys Therapeutics, Inc.

Capitalization 2.37B 2.02B 1.86B 1.76B 3.24B 223B 3.31B 21.81B 8.59B 107B 8.9B 8.72B 378B P/E ratio 2026 *
-13.1x
P/E ratio 2027 * -15.9x
Enterprise value 2.23B 1.91B 1.75B 1.65B 3.05B 210B 3.12B 20.53B 8.09B 100B 8.38B 8.21B 356B EV / Sales 2026 *
-
EV / Sales 2027 * 18.7x
Free-Float
88.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week-5.16%
Current month+6.50%
1 month+21.99%
3 months-15.84%
6 months-31.37%
Current year-20.50%
1 week 27.67
Extreme 27.67
31.48
1 month 22.42
Extreme 22.42
31.48
Current year 22.42
Extreme 22.42
37.7
1 year 12.59
Extreme 12.59
47.65
3 years 5.85
Extreme 5.85
47.65
5 years 5.85
Extreme 5.85
47.65
10 years 5.85
Extreme 5.85
47.65
Manager TitleAgeSince
Chief Executive Officer 62 2020-10-31
Director of Finance/CFO 48 2022-02-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 58 2021-01-31
Chairman 70 -
Director/Board Member 51 2023-09-12
Change 5d. change 1-year change 3-years change Capi.($)
+0.17%-5.16%+118.40%+110.58% 2.37B
-0.55%-4.80%-7.47%-12.17% 45.74B
-0.33%-2.84%+22.97%+20.77% 34.63B
-4.83%-7.07%+284.59%+515.54% 31.32B
-0.26%-1.71%+21.90%-13.76% 29.49B
+0.49%+2.46%+34.79%+32.44% 28.78B
-4.43%-4.99%+44.32%+187.89% 14.85B
-1.41%-1.97%+80.08%+171.46% 14.7B
-9.69%-8.53%+26.37%+2.45% 14.34B
+4.58%+0.21%+3,841.64%+4,135.60% 14.04B
Average -1.55%-0.48%+446.76%+515.08% 23.03B
Weighted average by Cap. -1.44%-0.85%+292.95%+349.69%

Financials

2026 *2027 *
Net sales - 118M 101M 92.41M 87.41M 161M 11.07B 165M 1.09B 428M 5.3B 443M 434M 18.82B
Net income -181M -155M -142M -134M -248M -17B -253M -1.67B -656M -8.14B -680M -666M -28.89B -156M -133M -122M -116M -213M -14.63B -218M -1.43B -565M -7.01B -585M -573M -24.87B
Net Debt -139M -119M -109M -103M -190M -13.06B -195M -1.28B -504M -6.26B -522M -512M -22.2B -168M -143M -131M -124M -229M -15.72B -234M -1.54B -607M -7.53B -629M -616M -26.72B
Logo Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Employees
76
Date Price Change Volume
26-04-22 28.83 $ +0.17% 322,694
26-04-21 28.78 $ -4.29% 1,062,600
26-04-20 30.07 $ -1.67% 573,262
26-04-17 30.58 $ +0.07% 1,040,439
26-04-16 30.56 $ +0.46% 1,379,934
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.78USD
Average target price
49.38USD
Spread / Average Target
+71.56%

Quarterly revenue - Rate of surprise